Table 2 Ongoing clinical trials of rociletinib (CO-1686)
From: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Phase | Study population | NCT no. |
|---|---|---|
Phase I/II | EGFR mutated advanced NSCLC | 02580708 |
Phase I/II | EGFR mutated advanced NSCLC | 02630186 |
Phase II/III (TIGER-1) | Untreated EGFR mutated advanced NSCLC | 02186301 |
Phase II (TIGER-2) | EGFR mutated NSCLC | 02147990 |
Phase III (TIGER-3) | EGFR mutated advanced NSCLC after failure of ≥1 previous EGFR TKI and platinum-doublet chemotherapy | 02322281 |